Peptide Vaccine

Phase 1Vaccine

UUniversity Hospital Tuebingen

Peptide Vaccine is one of 65 biologic programs targeting Kidney. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

KidneyRecruiting

NSCLC Stage IVRecruiting

TreatmentCompleted

KidneyPhase 1

Recruiting

NSCLC Stage IVPreclinical

Recruiting

TreatmentPreclinical

Completed

Competition

Competitive Landscape

350 competitors in Treatment

#DrugCompanyPhaseTrials

Dexilant

Takeda

Preclinical

2 2

Lamprene

Novartis

Preclinical

1 3

Emtriva

Gilead

Preclinical

1 4

Theo-Dur

Pfizer

Preclinical

1 5

Levulan

Sun Pharmaceutical Industries, Inc.

Preclinical

1 6

Foscavir

CClinigen, Inc.

Preclinical

6 7

Reminyl

WWim Janssens

Preclinical

1 8

Brevibloc

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 9

Sirturo

WWim Janssens

Preclinical

1 10

Clomid

Ferring

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Kidney

NCT06741072

Q3 2029

PreclinicalRecruiting

NSCLC Stage IV

NCT05950139

Clinical

Trials by Indication[1]

Glioblastoma1 trial

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

Withdrawn·NNYU Langone Health·Phase 2·NCT02754362

Adjuvant1 trial

Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00415857·5 enrolled

Renal Cell Carcinoma1 trial

Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides

Unknown status·UUniversity Hospital Tuebingen·Phase 1/2·NCT02429440·40 enrolled

First Line Therapy1 trial

iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL

Completed·UUniversity Hospital Tuebingen·Phase 2·NCT02802943·56 enrolled

Immunization1 trial

Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With Chronic HIV-infection

Completed·GGitte Kronborg·Phase 1·NCT01009762·11 enrolled

7 more indications

Melanoma1 trial

Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Completed·AAhmad Tarhini·Phase 1·NCT00471471·22 enrolled

Treatment1 trial

PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment

Completed·HH. Lee Moffitt Cancer Center and Research Institute·N/A·NCT00694551·29 enrolled

Malignancies1 trial

A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies

Withdrawn·HHadassah Medical Organization·Phase 2·NCT00162500·15 enrolled

Gastric Cancer1 trial

Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer

Completed·KKinki University·Phase 1·NCT00845611·9 enrolled

Biochemical Recurrence1 trial

Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy

Unknown status·UUniversity Hospital Tuebingen·Phase 1/2·NCT02452307·36 enrolled

NSCLC Stage IV1 trial

Pilot Study of a Prophylactic Cancer Peptide Vaccine in Advanced ALK+ NSCLC

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Preclinical·NCT05950139·12 enrolled

Kidney1 trial

A Phase 1B Double Blinded Randomized Trial Evaluating Safety, Tolerability, and Immune Response of OSU-2131 a BZLF1 Peptide Vaccine With Stimulon™ QS-21 Solution Adjuvant in Healthy Volunteers and Patients Awaiting Solid Organ Transplantation

Recruiting·OOhio State University Comprehensive Cancer Center·Phase 1·NCT06741072·55 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Peptide Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Peptide Vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Peptide Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital Tuebingen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 1[1]
Company: UUniversity Hospital Tuebingen

Peptide Vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2029

Trials by Indication[1]

Glioblastoma1 trial

Adjuvant1 trial

Renal Cell Carcinoma1 trial

First Line Therapy1 trial

Immunization1 trial

Melanoma1 trial

Treatment1 trial

Malignancies1 trial

Gastric Cancer1 trial

Biochemical Recurrence1 trial

NSCLC Stage IV1 trial

Kidney1 trial

References

Drug Info

Quick Facts

Related News